Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin in HFpEF Patients with Type 2 Diabetes Mellitus
ChiCTR2500096365Phase 4Suspended
- Sponsor
- Hubei Third People's Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of henagliflozin in heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hubei Third People's Hospital. Primary endpoints: Left ventricular end-diastolic volume (LVEDV) and Left ventricular end-systolic volume (LVESV). Started Jan 2025; status: suspended.
02
Drugs
henagliflozin
03
Conditions
heart failure with preserved ejection fraction (HFpEF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500096365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096365.